Wedbush Boosts Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $55.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective boosted by stock analysts at Wedbush from $46.00 to $55.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price target suggests a potential upside of 11.05% from the company’s previous close.

Other analysts have also recently issued reports about the company. HC Wainwright increased their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Truist Financial raised their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Finally, Jefferies Financial Group increased their price target on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $67.63.

Dianthus Therapeutics Trading Down 2.5%

NASDAQ:DNTH traded down $1.29 during mid-day trading on Wednesday, reaching $49.53. The company’s stock had a trading volume of 69,377 shares, compared to its average volume of 855,185. The stock has a market cap of $2.14 billion, a P/E ratio of -14.10 and a beta of 1.59. The firm’s fifty day moving average price is $44.77 and its two-hundred day moving average price is $36.70. Dianthus Therapeutics has a 12-month low of $13.36 and a 12-month high of $57.50.

Insiders Place Their Bets

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total value of $903,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 216,538 shares of company stock worth $8,283,175 in the last three months. Corporate insiders own 16.56% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Parkside Financial Bank & Trust boosted its holdings in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares during the period. Bessemer Group Inc. increased its stake in Dianthus Therapeutics by 7.8% during the third quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock worth $635,000 after acquiring an additional 1,170 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth about $27,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.